Stay updated on PD-L1+ NSCLC: Pembrolizumab vs Chemo Clinical Trial

Sign up to get notified when there's something new on the PD-L1+ NSCLC: Pembrolizumab vs Chemo Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the PD-L1+ NSCLC: Pembrolizumab vs Chemo Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    A site-wide banner announces NIH’s transition to using “Super Intelligence” instead of “Artificial Intelligence” and links to related updates and FAQs.
    Difference
    1%
    Check dated 2026-10-26T16:31:07.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    The website footer revision label changed from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-19T20:43:01.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    The footer revision identifier was updated from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-13T03:56:04.000Z thumbnail image
  4. Check
    38 days ago
    Change Detected
    Summary
    The page now renders a 403 Forbidden error with the site header and footer visible, replacing the previously accessible study content and related documents.
    Difference
    20%
    Check dated 2026-09-21T22:36:18.000Z thumbnail image
  5. Check
    59 days ago
    Change Detected
    Summary
    The page now displays a new revision label (v3.6.6) replacing the previous v3.6.5, reflecting a minor maintenance update to the site rather than substantive content changes.
    Difference
    0.1%
    Check dated 2026-08-31T16:59:51.000Z thumbnail image
  6. Check
    81 days ago
    Change Detected
    Summary
    The page revision tag was updated from v3.6.4 to v3.6.5, indicating a backend update; no user-facing study data or page content appears to be altered.
    Difference
    0.1%
    Check dated 2026-08-10T10:41:14.000Z thumbnail image

Stay in the know with updates to PD-L1+ NSCLC: Pembrolizumab vs Chemo Clinical Trial

Enter your email address, and we'll notify you when there's something new on the PD-L1+ NSCLC: Pembrolizumab vs Chemo Clinical Trial page.